Alzheimer’s Disease

Future importance of incorporating biomarkers into clinical practice

Aducanumab: what’s the latest?

Lecanemab for the treatment of early Alzheimer’s disease: the story so far

Lecanemab: Phase II open-label extension results

Comparing the research behind Alzheimer’s and Parkinson’s disease treatments

Major ongoing clinical trials in AD: aducanumab, donanemab & lecanemab

Phase III AHEAD 3-45 trial of lecanemab for preclinical Alzheimer’s disease

Bringing plasma biomarkers into clinical practice: what does the future hold?

Phase III ADMET2 trial of methylphenidate for apathy in Alzheimer’s Disease

Beyond Aβ and p-Tau: novel biomarkers under investigation for Alzheimer’s disease

The potential of NfL as a biomarker in neurodegenerative diseases

Highlights from AAIC: Targeting the immune response to treat AD

Inflammatory biomarkers for the prediction of dementia onset

The roles of inflammatory biomarkers in the pathogenesis of dementia

NfL as a biomarker in Alzheimer’s

Preliminary data on the use of SV2A as a biomarker of neurodegeneration in Alzheimer’s disease